![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
H Yamazaki, Z Guo, M Persmark, M Mimura, K Inoue, FP Guengerich and T Shimada
Osaka Prefectural Institute of Public Health, Japan.
Bufuralol 1'-hydroxylation is a prototypical reaction catalyzed by cytochrome P450 (P450) 2D6, an enzyme known to show debrisoquine/sparteine-type genetic polymorphism in humans. In the present study we further examined the roles of several human P450 enzymes, as well as P450 2D6, in the hydroxylation of (+/-)-bufuralol, using liver microsomes from several human samples and human P450 enzymes expressed in human lymphoblastoid cell lines or Escherichia coli. Kinetic analysis of bufuralol 1'-hydroxylation by liver microsomes showed that there were different Km and Vmax values in seven human samples examined; low Km values (approximately 0.05 mM) were observed in four samples (including sample HL-18), high Km values (approximately 0.25 mM) in two samples (including sample HL-67), and an intermediate Km value (approximately 0.1 mM) in one sample. Quinidine and anti-rat P450 2D1 antibody almost completely inhibited bufuralol 1'- hydroxylation in human sample HL-18 at a substrate concentration of 0.4 mM, whereas these effects were not so drastic when liver microsomes from human sample HL-67 were used. In contrast, a very low concentration (< 10 microM) of alpha-naphthoflavone or anti-human P450 1A2 antibody significantly inhibited bufuralol 1'-hydroxylation catalyzed by human sample HL-67, but not HL-18, with 0.4 mM bufuralol. When the relative contents of P450 2D6 and P450 1A2 in 20 human samples were determined, bufuralol 1'-hydroxylation in samples containing large amounts of P450 2D6 tended to be more sensitive to quinidine, whereas the P450 1A2-rich samples were highly susceptible to alpha- naphthoflavone. However, at low substrate concentrations bufuralol 1'- hydroxylation was shown to be catalyzed principally by P450 2D6, based on the inhibitory effects of anti-rat P450 2D1 antibody and quinidine, in both human samples HL-18 and HL-67. At least five other, minor, bufuralol products were formed by human liver microsomes, in addition to 1'-hydroxybufuralol. Two of them were identified as 4- and 6- hydroxybufuralol by 1H NMR spectroscopy and mass spectrometry. The formation of the 4- and 6-hydroxylated products was suggested to be catalyzed by P450 1A2, based on the results of correlation with P450 1A2 contents in 60 human samples and inhibition by anti-P450 1A2 and alpha-naphthoflavone. Purified recombinant P450 1A2 (expressed in E. coli) produced 1'-, 4-, and 6-hydroxybufuralol in a reconstituted system, although P450 2D6 (expressed in human lymphoblast cell lines) was found to catalyze only bufuralol 1'-hydroxylation.(ABSTRACT TRUNCATED AT 400 WORDS)
This article has been cited by other articles:
|
|
 |
|
  S. Blech, T. Ebner, E. Ludwig-Schwellinger, J. Stangier, and W. Roth The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans Drug Metab. Dispos., February 1, 2008; 36(2): 386 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Foti and M. B. Fisher IMPACT OF INCUBATION CONDITIONS ON BUFURALOL HUMAN CLEARANCE PREDICTIONS: ENZYME LABILITY AND NONSPECIFIC BINDING Drug Metab. Dispos., March 1, 2004; 32(3): 295 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Narimatsu, C. Takemi, D. Tsuzuki, H. Kataoka, S. Yamamoto, N. Shimada, S. Suzuki, T. Satoh, U. A. Meyer, and F. J. Gonzalez Stereoselective Metabolism of Bufuralol Racemate and Enantiomers in Human Liver Microsomes J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 172 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hiroi, T. Chow, S. Imaoka, and Y. Funae Catalytic Specificity of CYP2D Isoforms in Rat and Human Drug Metab. Dispos., September 1, 2002; 30(9): 970 - 976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. H. Hanna, J. A. Krauser, H. Cai, M.-S. Kim, and F. P. Guengerich Diversity in Mechanisms of Substrate Oxidation by Cytochrome P450 2D6. LACK OF AN ALLOSTERIC ROLE OF NADPH-CYTOCHROME P450 REDUCTASE IN CATALYTIC REGIOSELECTIVITY J. Biol. Chem., October 19, 2001; 276(43): 39553 - 39561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. J. Chun, S. Y. Ryu, T. C. Jeong, and M. Y. Kim Mechanism-Based Inhibition of Human Cytochrome P450 1A1 by Rhapontigenin Drug Metab. Dispos., April 1, 2001; 29(4): 389 - 393. [Abstract] [Full Text]
|
|
|
|
|
|
J.-S. Wang, J. T. Backman, P. Taavitsainen, P. J. Neuvonen, and K. T. Kivistö Involvement of CYP1A2 and CYP3A4 in Lidocaine N-Deethylation and 3-Hydroxylation in Humans Drug Metab. Dispos., August 1, 2000; 28(8): 959 - 965. [Abstract] [Full Text]
|
|
|
|
|
|
M. Nakajima, S. Nakamura, S. Tokudome, N. Shimada, H. Yamazaki, and T. Yokoi Azelastine N-Demethylation by Cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in Human Liver Microsomes: Evaluation of Approach to Predict the Contribution of Multiple CYPs Drug Metab. Dispos., December 1, 1999; 27(12): 1381 - 1391. [Abstract] [Full Text]
|
|
|
|
|
|
D. A. Erickson, G. Mather, W. F. Trager, R. H. Levy, and J. J. Keirns Characterization of the In Vitro Biotransformation of the HIV-1 Reverse Transcriptase Inhibitor Nevirapine by Human Hepatic Cytochromes P-450 Drug Metab. Dispos., December 1, 1999; 27(12): 1488 - 1495. [Abstract] [Full Text]
|
|
|
|
|
|
T. Shimada, F. Tsumura, and H. Yamazaki Prediction of Human Liver Microsomal Oxidations of 7-Ethoxycoumarin and Chlorzoxazone with Kinetic Parameters of Recombinant Cytochrome P-450 Enzymes Drug Metab. Dispos., November 1, 1999; 27(11): 1274 - 1280. [Abstract] [Full Text]
|
|
|
|
|
|
D. C. Mankowski The Role of CYP2C19 in the Metabolism of (+/-) Bufuralol, the Prototypic Substrate of CYP2D6 Drug Metab. Dispos., September 1, 1999; 27(9): 1024 - 1028. [Abstract] [Full Text]
|
|
|
|
|
|
B. C. Jones, R. Hyland, M. Ackland, C. A. Tyman, and D. A. Smith Interaction of Terfenadine and Its Primary Metabolites with Cytochrome P450 2D6 Drug Metab. Dispos., September 1, 1998; 26(9): 875 - 882. [Abstract] [Full Text]
|
|
|
|
|
|
V. Fischer, A. Rodríguez-Gascón, F. Heitz, R. Tynes, C. Hauck, D. Cohen, and A. E. M. Vickers The Multidrug Resistance Modulator Valspodar (PSC 833) Is Metabolized by Human Cytochrome P450 3A. Implications for Drug-Drug Interactions and Pharmacological Activity of the Main Metabolite Drug Metab. Dispos., August 1, 1998; 26(8): 802 - 811. [Abstract] [Full Text]
|
|
|
|
|
|
H. Yamazaki, K. Inoue, P. M. Shaw, W. J. Checovich, F. P. Guengerich, and T. Shimada Different Contributions of Cytochrome P450 2C19 and 3A4 in the Oxidation of Omeprazole by Human Liver Microsomes: Effects of Contents of These Two Forms in Individual Human Samples J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 434 - 442. [Abstract] [Full Text]
|
|
|
|
|
|
E. L. Code, C. L. Crespi, B. W. Penman, F. J. Gonzalez, T. K. H. Chang, and D. J. Waxman Human Cytochrome P4502B6. Interindividual Hepatic Expression, Substrate Specificity, and Role in Procarcinogen Activation Drug Metab. Dispos., August 1, 1997; 25(8): 985 - 993. [Abstract] [Full Text]
|
|
|
|
|
|
T. Shimada, E. M. J. Gillam, T. R. Sutter, P. T. Strickland, F. P. Guengerich, and H. Yamazaki Oxidation of Xenobiotics by Recombinant Human Cytochrome P450 1B1 Drug Metab. Dispos., May 1, 1997; 25(5): 617 - 622. [Abstract] [Full Text]
|
|
|
|
|
|
H. Yamazaki, K. Inoue, C. G. Turvy, F. P. Guengerich, and T. Shimada Effects of Freezing, Thawing, and Storage of Human Liver Samples on the Microsomal Contents and Activities of Cytochrome P450 Enzymes Drug Metab. Dispos., February 1, 1997; 25(2): 168 - 174. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
